Immunocore (IMCR)
(Delayed Data from NSDQ)
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Zacks News
Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 60.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
by Zacks Equity Research
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
by Zacks Equity Research
Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate
by Zacks Equity Research
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold
by Zacks Equity Research
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and vTv Therapeutics (VTVT) have performed compared to their sector so far this year.
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
by Zacks Equity Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
by Zacks Equity Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study
by Zacks Equity Research
Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study
by Zacks Equity Research
Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
by Zacks Equity Research
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
by Zacks Equity Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Does Immunocore Holdings PLC Sponsored ADR (IMCR) Have the Potential to Rally 45% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 44.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Momentum in Immunocore Holdings PLC Sponsored ADR (IMCR) Should Keep going
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 32%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 31.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.
Zacks.com featured highlights Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource
by Zacks Equity Research
Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource have been highlighted in this Screen of The Week article.
Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.